WATERTOWN, Mass. and GOSSELIES, Belgium, May 12, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today reported financial results for the first quarter ended March 31, 2022 and provided recent corporate highlights.
Read more at globenewswire.comhello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
